MA52945A - Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents - Google Patents
Procédé de production d'un mélange contrôlé d'au moins deux anticorps différentsInfo
- Publication number
- MA52945A MA52945A MA052945A MA52945A MA52945A MA 52945 A MA52945 A MA 52945A MA 052945 A MA052945 A MA 052945A MA 52945 A MA52945 A MA 52945A MA 52945 A MA52945 A MA 52945A
- Authority
- MA
- Morocco
- Prior art keywords
- producing
- different antibodies
- controlled mixture
- mixture
- controlled
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18179365 | 2018-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52945A true MA52945A (fr) | 2021-04-28 |
Family
ID=62841830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052945A MA52945A (fr) | 2018-06-22 | 2019-06-24 | Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210269509A1 (fr) |
EP (1) | EP3810649A1 (fr) |
JP (1) | JP2021528435A (fr) |
CN (1) | CN112513074A (fr) |
CA (1) | CA3104390A1 (fr) |
IL (1) | IL279528A (fr) |
MA (1) | MA52945A (fr) |
SG (1) | SG11202012713RA (fr) |
WO (1) | WO2019243626A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023514692A (ja) | 2020-02-21 | 2023-04-07 | ジェンマブ ビー.ブイ. | 糖蛋白質の定量のための方法 |
KR20240032959A (ko) * | 2021-07-14 | 2024-03-12 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Hgfr 및 egfr에 특이적으로 결합하는 항원-결합 분자, 및 이의 약학적 용도 |
WO2024109914A1 (fr) * | 2022-11-24 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | Composition pharmaceutique comprenant un anticorps bispécifique se liant spécifiquement à hgfr et à egfr |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
WO2000005266A1 (fr) | 1998-07-21 | 2000-02-03 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Anticorps contre le virus de l'hepatite c et ses utilisations |
WO2004009618A2 (fr) * | 2002-07-18 | 2004-01-29 | Crucell Holland B.V. | Production par recombinaison de melanges d'anticorps |
MXPA03011365A (es) | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
DK3284753T3 (da) | 2002-10-17 | 2021-07-05 | Genmab As | Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose |
MXPA05006724A (es) | 2003-01-07 | 2005-09-08 | Symphogen As | Metodo para producir proteinas policlonales recombinantes. |
NZ552264A (en) * | 2004-07-20 | 2010-03-26 | Symphogen As | A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
NZ552265A (en) * | 2004-07-20 | 2009-04-30 | Symphogen As | Anti-rhesus D recombinant polyclonal antibody and methods of manufacture |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
DK2152872T3 (da) | 2007-05-25 | 2010-12-06 | Symphogen As | Fremgangsmåde til fremstilling af et rekombinant polyklonalt protein |
RU2010147652A (ru) * | 2008-04-23 | 2012-05-27 | Симфоген А/С (Dk) | Способы производства поликлонального белка |
DK2393927T3 (en) | 2009-02-09 | 2015-03-30 | Morphosys Ag | Preparation of oligoclonal mixtures of antibodies in the individual cells |
KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
SG10202001677QA (en) | 2010-03-12 | 2020-04-29 | Debiopharm International S A | Cd37-binding molecules and immunoconjugates thereof |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
EP2575880B1 (fr) | 2010-05-27 | 2019-01-16 | Genmab A/S | Anticorps monoclonaux contre l'épitope de her2 |
DK2640743T3 (en) | 2010-11-16 | 2017-01-23 | Excelimmune Inc | PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS |
CA2832387A1 (fr) | 2011-04-20 | 2012-10-26 | Genmab A/S | Anticorps bispecifiques contre her2 |
UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
US10047144B2 (en) | 2011-10-19 | 2018-08-14 | Novimmune Sa | Methods of purifying antibodies |
AU2013234039B2 (en) | 2012-03-13 | 2018-02-01 | Novimmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
EP3401337A1 (fr) | 2012-09-25 | 2018-11-14 | Glenmark Pharmaceuticals S.A. | Purification d'immunoglobulines hétérodimères |
CN113735967A (zh) | 2013-01-10 | 2021-12-03 | 根马布私人有限公司 | 人类IgG1 FC区变体及其用途 |
CA2909969A1 (fr) | 2013-05-13 | 2014-12-31 | Medimmune, Llc | Separation de multimeres d'anticorps polyclonaux de recombinaison avec une separation minimale des monomeres |
RS60012B1 (sr) | 2014-07-11 | 2020-04-30 | Genmab As | Antitela koja vezuju axl |
EP3233907B1 (fr) * | 2014-12-19 | 2021-03-03 | Genmab A/S | Protéines hétérodimères bispécifiques de rongeurs |
IL264631B2 (en) * | 2016-08-16 | 2024-05-01 | Regeneron Pharma | A method for quantifying individual antibodies from a mixture |
-
2019
- 2019-06-24 CA CA3104390A patent/CA3104390A1/fr active Pending
- 2019-06-24 SG SG11202012713RA patent/SG11202012713RA/en unknown
- 2019-06-24 MA MA052945A patent/MA52945A/fr unknown
- 2019-06-24 US US17/253,286 patent/US20210269509A1/en active Pending
- 2019-06-24 WO PCT/EP2019/066594 patent/WO2019243626A1/fr unknown
- 2019-06-24 JP JP2020571498A patent/JP2021528435A/ja active Pending
- 2019-06-24 EP EP19734332.0A patent/EP3810649A1/fr active Pending
- 2019-06-24 CN CN201980050655.0A patent/CN112513074A/zh active Pending
-
2020
- 2020-12-17 IL IL279528A patent/IL279528A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3810649A1 (fr) | 2021-04-28 |
CA3104390A1 (fr) | 2019-12-26 |
CN112513074A (zh) | 2021-03-16 |
IL279528A (en) | 2021-01-31 |
WO2019243626A1 (fr) | 2019-12-26 |
SG11202012713RA (en) | 2021-01-28 |
US20210269509A1 (en) | 2021-09-02 |
JP2021528435A (ja) | 2021-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52945A (fr) | Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents | |
MA53673A (fr) | Procédé de production d'un dérivé de 4-méthoxy pyrrole | |
MA48723A (fr) | Procédé de production d'anticorps multispécifiques | |
MA53920A (fr) | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 | |
MA41200B1 (fr) | Procédé pour la préparation d'un composé diarylthiohydantoïne | |
MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
MA42539A (fr) | Mélange pour la construction de produits infrastructuraux et structuraux et procédé de production associé | |
PH12019502093A1 (en) | Novel ester compounds, method for the production thereof and use thereof | |
BR112018073490A2 (pt) | 6.7.beta-epóxidos esteroides como intermediários químicos | |
MA45768A (fr) | Procédé pour la préparation de compositions d'immunoglobulines | |
MA50170A (fr) | Procédé et système de production d'un mélange gazeux | |
WO2015124764A8 (fr) | Procédé de synthèse de dabigatran étexilate mésylate, intermédiaires de ce procédé et nouveau polymorphe de dabigatran étexilate | |
MA54248A (fr) | Régulation de métaux traces pendant la production d'anticorps anti-cd38 | |
MA52755A (fr) | Procédé d'enrobage d'engrais | |
MA56129A (fr) | Procédés de production d'un anticorps anti-alpha4béta7 | |
MA51420A (fr) | Inoculant de fonte et procédé de production d'un inoculant de fonte | |
MA50838A (fr) | Procédés de production de matieres végétales ensilées à l'aide de megasphaera elsdenii | |
MA50859A (fr) | Procédé pour la production d'une composition de lymphocytes t | |
MA51913A (fr) | Composition granulaire, procédé de production d'une composition granulaire et procédé d'amélioration de la propriété d'élution d'une composition granulaire | |
MA54299A (fr) | Procédés de production de compositions d'allergènes mixtes | |
MA50983A (fr) | Procédé pour la fabrication d'un disque composite | |
MA51339A (fr) | Procédé de préparation de composés pyrimidinyl-4-aminopyrazole | |
MA49555A (fr) | Procédé amélioré de préparation d'imetelstat | |
MA46790A (fr) | Tuile modulaire, latte fonctionnalisée, tuyau et procédé de production d'un tuyau | |
FR3053331B1 (fr) | Procede de production de butadiene a partir d'ethanol integre avec distillation extractive |